Advertising Disclaimer
Published online March 2, 2009
PEDIATRICS Vol. 123 No. 3 March 2009, pp. 924-934 (doi:10.1542/peds.2008-0642)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View eLetters
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lewis, D.
Right arrow Articles by Ford, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lewis, D.
Right arrow Articles by Ford, L.
Related Collections
Right arrow Therapeutics & Toxicology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for Migraine Prevention in Pediatric Subjects 12 to 17 Years of Age

Donald Lewis, MDa, Paul Winner, DOb, Joel Saper, MDc, Seth Ness, MD, PhDd, Elena Polverejan, PhDd, Steven Wang, PhDd, Caryn L. Kurland, PhDd, Jeff Nye, MD, PhDd, Eric Yuen, MDd, Marielle Eerdekens, MDe, Lisa Ford, MDd

a Department of Pediatrics, Division of Pediatric Neurology, Children's Hospital of the King's Daughters, Eastern Virginia Medical School, Norfolk, Virginia
b Department of Neurology, Palm Beach Headache Center/Palm Beach Neurology, West Palm Beach, Florida
c Department of Neurology, Michigan Head Pain and Neurological Institute, Ann Arbor, Michigan
d Department of Therapeutics, Johnson & Johnson Pharmaceutical Research and Development, Titusville, New Jersey
e Department of Therapeutics, Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium

OBJECTIVE. Currently, no drugs are Food and Drug Administration-approved for migraine prophylaxis in pediatric patients. The objective of this study was to evaluate the efficacy and safety of topiramate for migraine prevention in adolescents.

METHODS. Adolescents (12–17 years of age) with a ≥6-month history of migraine were assigned randomly to receive 16 weeks of daily treatment with topiramate (50 or 100 mg/day) or placebo. The primary efficacy measure was the percent reduction in monthly migraine attacks, with the use of the 48-hour rule, from the prospective baseline period to the last 12 weeks of the double-blind phase. The 48-hour rule defined a single migraine episode as all recurrences of migraine symptoms within 48 hours after onset. Several secondary efficacy measures were evaluated, including the reduction from baseline in the monthly migraine day rate and the 50% responder rate. Safety and tolerability were also assessed.

RESULTS. A total of 29 (83%) of 35 subjects treated with topiramate at 50 mg/day, 30 (86%) of 35 subjects treated with topiramate at 100 mg/day, and 26 (79.0%) of 33 placebo-treated subjects completed double-blind treatment. Topiramate at 100 mg/day, but not 50 mg/day, resulted in a statistically significant reduction in the monthly migraine attack rate from baseline versus placebo (median: 72.2% vs 44.4%) during the last 12 weeks of double-blind treatment. Topiramate at 100 mg/day, but not 50 mg/day, also resulted in a statistically significant reduction in the monthly migraine day rate from baseline versus placebo. The responder rate favored topiramate at 100 mg/day (83% vs 45% for placebo). Upper respiratory tract infection, paresthesia, and dizziness occurred more commonly in the topiramate groups than in the placebo group.

CONCLUSIONS. The 100 mg/day topiramate group demonstrated efficacy in the prevention of migraine in pediatric subjects. Overall, topiramate treatment was safe and well tolerated.

Key Words: migraine prevention • adolescents • topiramate • prophylactic treatment

Accepted Jul 21, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
K. J. Mack and A. D. Hershey
Chronic daily headache in adolescence: A continuing problem
Neurology, August 11, 2009; 73(6): 412 - 413.
[Full Text] [PDF]

eLetters:

Read all eLetters

? Gender Bias
Michael D. Schwartz
Pediatrics Online, 12 Mar 2009 [Full text]
Safety considerations in prescribing topiramate in adolescents
Ram Kumar, et al.
Pediatrics Online, 10 Jun 2009 [Full text]